Jim Cramer's top 10 things to watch in the stock market Wednesday

Treasury will more than double government debt purchases, lifting futures after recent yield volatility—framed as a policy “put” to support risk assets. Stock-specific catalysts are highly mixed: Moderna surged ~90%+ on promising late-stage melanoma cancer vaccine data (Merck up ~7%), while Klarna slid ~23% after weak guidance and SK Hynix announced a $29B buyback (shares up ~4% premarket). Meanwhile, Target and Lowe’s posted results with divergence (Target raised full-year guidance; Lowe’s cut outlook after missing revenue/same-store sales), while several analysts upgraded Nokia (AI networking) and Cardinal Health (buy, $276 target).

Analysis

The Treasury bid is more important as a liquidity signal than as a macro inflection: it mechanically lowers the discount rate on long-duration assets and eases refinancing pressure, but it does not fix the underlying fiscal supply overhang. That favors growth, software, and other high-multiple proxies in the near term, while also supporting levered balance-sheet names; the falsifier is a quick re-steepening of the curve or a failed auction that tells you the market is still demanding a higher term premium.

In healthcare, the melanoma readout is less about one asset and more about validating an oncology platform with real partnering optionality. MRK is the cleaner expression because the trial success extends the life of a dominant franchise and lowers headline pipeline risk, while MRNA remains a binary, sentiment-heavy vehicle that can give back a large chunk of the move if later-stage data, manufacturing, or label scope disappoints. In semis, the SK Hynix buyback is sentiment-positive for MU and the whole memory chain, but it does not change the supply discipline question; the real catalyst is whether DRAM ASPs keep rising into the next capex cycle.

Retail remains a relative-value game, not a broad-demand recovery. HD still has the better mix because pro demand is steadier than DIY, while LOW’s miss suggests the housing slump is still leaking into transaction volumes; TJX and TGT look more like share-gain stories than demand reacceleration, so chasing the beat is risky. The contrarian miss is that the market may be underpricing the duration of the BNPL reset: KLAR’s problem is not one bad quarter, it is a higher-funding-cost, lower-tolerance credit regime that can compress multiples for months unless loss trends improve materially.

Key Decisions for Investors

• Long MRK on the first 2-3 day pullback; 1-3 month horizon. Best risk/reward is owning the platform validation without paying the peak gap-up premium. Falsifier: any material softening in oncology guidance or commentary that pushes commercialization beyond 2026.
• Buy MU on weakness over the next 1-2 weeks; pair against a weaker data-center basket if borrow is available. Horizon 3-6 months, with upside if DRAM pricing stays firm. Falsifier: signs that the Korean buyback is masking deteriorating pricing power or capex discipline breaks.
• Initiate long HD / short LOW as a relative-value pair for 1-3 months. HD should keep outperforming if housing stays frozen and pro spend holds up. Falsifier: a clear inflection in LOW comps or mortgage rates that revives DIY activity.
• Avoid chasing KLAR; if liquidity permits, use any bounce to short or buy puts for a 4-8 week trade. The thesis is multiple compression from slower growth plus credit normalization. Falsifier: two consecutive clean quarters with improving credit metrics and raised take-rate guidance.
• Accumulate SBUX on coffee-deflation weakness for a 6-12 month turnaround trade, not a tactical pop. Lower input costs matter only if traffic and mix improve under the new operating plan. Falsifier: margin relief getting offset by continued traffic underperformance.